Piper Sandler cut shares of Oncorus (NASDAQ:ONCR – Get Rating) from an overweight rating to a neutral rating in a research report released on Wednesday, The Fly reports. Piper Sandler currently has $2.00 target price on the stock, down from their prior target price of $6.00.

Oncorus Trading Up 2.1 %

Shares of ONCR stock opened at $0.46 on Wednesday. The business's fifty day moving average price is $0.69 and its 200 day moving average price is $1.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.97 and a quick ratio of 4.97. The firm has a market capitalization of $11.93 million, a PE ratio of -0.16 and a beta of 2.24. Oncorus has a 1-year low of $0.41 and a 1-year high of $6.08.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ONCR. Goldman Sachs Group Inc. lifted its stake in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock valued at $148,000 after purchasing an additional 30,668 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Oncorus during the second quarter worth $476,000. Renaissance Technologies LLC lifted its holdings in Oncorus by 23.9% in the second quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Sawtooth Solutions LLC lifted its holdings in shares of Oncorus by 22.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 77,336 shares of the company's stock worth $97,000 after purchasing an additional 14,433 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Oncorus by 28.9% during the second quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock valued at $103,000 after acquiring an additional 18,220 shares during the period. Institutional investors and hedge funds own 65.89% of the company's stock.

Oncorus Company Profile

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Stories

• Get a free copy of the StockNews.com research report on Oncorus (ONCR)
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?
• Can ZIM Defy Broad Downturn In The Container Shipping Industry?

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.